Insmed (INSM) vs Teva Pharmaceutical Industries (TEVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Teva Pharmaceutical Industries (TEVA) has outperformed Insmed (INSM) over the past year, gaining 62.0% versus a loss of 28.9%. Over five years, INSM leads with a +388.5% price change compared with +362.1% for TEVA. Teva Pharmaceutical Industries is the larger company by market cap ($45.77 billion vs $31.01 billion), about 1.5 times the size, while Insmed is growing revenue faster (+66.7% vs +4.3%).
On valuation, Teva Pharmaceutical Industries trades at a lower forward P/E (12.5x vs 220.2x for Insmed). Teva Pharmaceutical Industries converts more of its revenue into profit, with a net margin of 8.2% versus -210.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INSM | TEVA |
|---|---|---|
| Share price | $141.33 | $39.23 |
| Market cap | $31.01B | $45.77B |
| 1-day change | -2.17% | +1.79% |
| YTD return | -18.79% | +25.70% |
| 1-year return | -28.89% | +62.04% |
| 5-year return | +388.52% | +362.07% |
| P/E ratio (TTM) | — | 91.23 |
| Forward P/E | 220.18 | 12.53 |
| EPS (TTM) | $-2.81 | $0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $606.42M | $17.26B |
| Revenue growth (YoY) | +66.73% | +4.32% |
| Net income (latest FY) | $-1.28B | $1.41B |
| Gross margin | 79.73% | 51.79% |
| Operating margin | -205.59% | 12.50% |
| Net margin | -210.54% | 8.17% |
| 52-week high | $212.75 | $44.57 |
| 52-week low | $90.39 | $24.34 |
| Distance from 52-week high | -33.57% | -11.98% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +37.39% | +28.19% |
| Average volume | 3.09M | 6.31M |
| Shares outstanding | 219.38M | 1.17B |
| Employees | 1,664 | 31,173 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TEVA has outperformed INSM by 90.9 percentage points over the past year.
- Teva Pharmaceutical Industries is more profitable, keeping 8.2 cents of every revenue dollar as net income versus -210.5 cents for Insmed.
- Insmed grew revenue faster in its latest fiscal year (+66.73% vs +4.32%).
About Insmed
INSM stock →Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,664 employees
About Teva Pharmaceutical Industries
TEVA stock →Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Health Care · Biotechnology: Pharmaceutical Preparations · 31,173 employees
INSM vs TEVA FAQ
Which is bigger, Insmed or Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries (TEVA) is larger, with a market capitalization of $45.77B compared with $31.01B for Insmed (INSM).
Which stock has performed better over the past year, INSM or TEVA?
TEVA returned +62.04% over the past 12 months, compared with -28.89% for INSM (price return, excluding dividends). Past performance does not predict future results.
Are Insmed and Teva Pharmaceutical Industries in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.